- Home
- » Tags
- » Favipiravir
Top View
- Protease Inhibitors (Ritonavir and ASC09) in Clinical Trials to Treat COVID-19, the Illness Caused by the New Coronavirus (Table 1)
- Being Pregnant During the Kivu Ebola Virus Outbreak
- Use of Favipiravir to Treat Lassa Virus Infection in Macaques
- Pharmacotherapy of Ebola Hemorrhagic Fever: a Brief Review of Current Status and Future Perspectives
- Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: from Animal Studies to Clinical Trials
- Antiviral Drugs Proposed for COVID-19: Action Mechanism and Pharmacological Data
- Ebola Virus Disease
- Favipiravir at High Doses Has Potent Antiviral Activity in SARS-Cov-2−Infected Hamsters, Whereas Hydroxychloroquine Lacks Activity
- Favipiravir in Therapy of Viral Infections
- Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs Md N
- 1 Identification of Potent Drugs and Antiviral Agents for the Treatment Of
- Antiviral Therapeutic Approaches for SARS-Cov-2 Infection: a Systematic Review
- Safety and Efficacy of Favipiravir Versus Hydroxychloroquine in Management of COVID-19: a Randomised Controlled Trial
- T-705 (Favipiravir) Activity Against Lethal H5N1 Influenza a Viruses
- As a Treatment Type for COVID-19
- Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
- Antiviral Medications and Plasma Efficacy in Treating Ebola Patients: a Systematic Review
- Drugs Intervention Study in COVID-19 Management
- Ocular Manifestations of COVID-19 (SARS-Cov-2): a Critical Review of Current Literature KONSTANTINOS A.A
- Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence
- COVID-19 Issues Issue 3
- Researchers Race to Develop Antiviral Weapons to Ght the Pandemic
- Favipiravir (T-705) Protects Against Nipah Virus Infection in the Hamster Model Received: 17 November 2017 Brian E
- Ebola Virus Disease
- Maporal Hantavirus Β-Integrin Utilization and Sensitivity to Favipiravir
- Antiviral Drugs Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Triggering the Coronavirus Disease‑19 Pandemic Rashed Noor*
- NIH Public Access Author Manuscript Antiviral Res
- Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2019
- An Overview of COVID-19 Medicines in Current Guidelines
- Russian Pharmaceutical Market 2020 (Pdf, 3.8
- Therapeutic Options for the 2019 Novel Coronavirus (2019-Ncov)
- COVID-19 Therapeutic Research and Development Landscape
- The Efficacy and Safety of Favipiravir in Treatment of COVID-19
- Recently Published Data on Favipiravir As Treatment for Mild to Moderate COVID-19 Demonstrates Significant Improvement in Time to Clinical Cure
- A Systematic Review of Antiviral Drugs for the Treatment of the COVID-19 Pandemic
- Maternal and Infant Death and the Rvsv-ZEBOV Vaccine Through
- In Silico Studies Predict Efficient Binding of Remdesivir and Favipiravir with 3-Chymotrypsin Like Protease of SARS-Cov-2 for COVID-19 Interventional Therapy
- Favipiravir May Acts As COVID-19 Main Protease PDB ID 6LU7 Inhibitor: Docking Analysis
- 20219 WHO Living Guideline -Therapeutics and COVID-19
- Ebola Virus Disease
- Potential Prophylactic Treatments for COVID-19
- Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease
- Small Molecule Inhibitors of Ebola Virus Infection, with >60 Examples, Including Approved Drugs
- Molecular Mechanism of Action of Repurposed Drugs and Traditional
- Remdesivir from Wikipedia, the Free Encyclopedia
- Ebola Virus Disease
- ESAC-Net Reporting Protocol 2019.Docx
- Identification of EIDD-1931, Favipiravir and Suramin As Mayaro Virus
- Covid-19: UK Launches Antivirals Taskforce to Deliver Home
- Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
- Guidelines for Clinical Practice, Diagnosis, Treatment and Prevention
- National Guidelines for Clinical Management and Treatment of COVID-19 1St June, 2020 Version 4.0
- Overview of Therapeutic Drug Research for COVID-19 in China
- Supplementary Table II
- COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical
- Assessment of Evidence for COVID-19-Related Treatments
- Market Access Q&A Emergency Legislation / Regulatory Relaxation During COVID-19 Pandemic
- Favipiravir, an Anti-Influenza Drug Against Life-Threatening RNA Virus
- And Ribavirin on Influenza Virus Replication and Viral RNA Synthesis
- EBOLA in Sierra Leone Lessons Learnt Dr Marta Lado Infectious Diseases Coordinator Kings Sierra Leone Partnership, KSLP
- The Significance of Natural Product Derivatives and Traditional
- New Treatment Strategies for Influenza Luis Del Carpio-Orantes*
- SARS-Cov-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy
- Beschlussfassung Der Arbeitsgruppe ATC/DDD Des Kuratoriums Für Fragen Der Klassifikation Im Gesundheitswesen